Prochymal（クローン病治療薬）：市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Symptoms 15
3.3 Prognosis 16
3.4 Quality of Life 16
4 Disease Management 17
4.1 Treatment Overview 18
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Opportunity and Unmet Need 26
6.1 Overview 26
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 27
6.3 More Therapies for Anti-TNF-Refractory Patients 28
6.4 Unmet Needs Gap Analysis 29
6.5 Targeted Therapies 30
6.6 Predictive Tools for Early Diagnosis and Treatment 31
7 Pipeline Assessment 32
7.1 Overview 32
7.2 Promising Drugs in Clinical Development 32
8 Prochymal (remestemcel-L) 35
8.1 Overview 35
8.2 Efficacy 36
8.3 Safety 37
8.4 Dosing and Formulation 37
8.5 Potential Clinical Positioning 37
8.6 Potential Commercial Positioning 38
8.7 Pricing and Reimbursement 38
8.8 SWOT Analysis 39
8.9 Forecast 40
9 Appendix 42
9.1 Bibliography 42
9.2 Abbreviations 45
9.3 Methodology 47
9.4 Forecasting Methodology 47
9.4.1 Diagnosed CD Patients 48
9.4.2 Percent Drug-Treated Patients 48
9.4.3 General Pricing Assumptions 48
9.4.4 Generic Erosion 50
9.4.5 Pricing of Pipeline agents 50
9.5 Physicians and Specialists Included in This Study 50
9.6 Primary Research – Prescriber Survey 52
9.7 About the Authors 53
9.7.1 Author/Reviewer 53
9.7.2 Global Head of Healthcare 53
9.8 About GlobalData 54
9.9 Disclaimer 54